Who owns LEXEO THERAPEUTICS INC?
- Ticker: LXEO
- CUSIP Number: 52886x107
Tip: Access positions for across all investors
Analyze quarterly positions in Lexeo Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Lexeo Therapeutics stock
Who bought or sold LEXEO THERAPEUTICS INC this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Henderson Group | 3.2M | $51M | 25% | Jun 2024 |
|
Citadel Advisors | 2.7M | $25M | 6% | Sep 2024 |
|
Omega Fund Management | 2.4M | $38M | 0% | Jun 2024 |
|
Eventide Asset Management | 1.9M | $17M | -45% | Sep 2024 |
|
BlackRock | 1.6M | $15M | 100% | Sep 2024 |
|
Frazier Life Sciences Management | 1.3M | $11M | 100% | Sep 2024 |
|
Blackstone Group | 1.2M | $11M | 44% | Sep 2024 |
|
Novo A/S | 1.1M | $10M | -23% | Sep 2024 |
|
Woodline Partners | 852k | $7.7M | 3% | Sep 2024 |
|
Vestal Point Capital | 850k | $7.7M | 1% | Sep 2024 |
|
BlackRock | 792k | $13M | 19% | Jun 2024 |
|
Braidwell | 729k | $6.6M | -47% | Sep 2024 |
|
Vanguard Group | 630k | $10M | 31% | Jun 2024 |
|
Siren | 603k | $5.5M | 100% | Sep 2024 |
|
Geode Capital Management | 553k | $5.0M | 87% | Sep 2024 |
|
RA Capital Management | 547k | $4.9M | -19% | Sep 2024 |
|
Verition Fund Management | 421k | $6.8M | 593% | Jun 2024 |
|
Point72 Asset Management | 370k | $3.3M | 100% | Sep 2024 |
|
Laurion Capital Management | 260k | $2.4M | -43% | Sep 2024 |
|
Ikarian Capital | 257k | $2.3M | 100% | Sep 2024 |
|
DAFNA Capital Management | 251k | $2.3M | 100% | Sep 2024 |
|
Northern Trust | 200k | $1.8M | 144% | Sep 2024 |
|
State Street Corporation | 196k | $3.1M | 75% | Jun 2024 |
|
Perceptive Advisors | 140k | $1.3M | 100% | Sep 2024 |
|
Charles Schwab Investment Management | 64k | $577k | 107% | Sep 2024 |
|
Polar Securities | 60k | $541k | -8% | Sep 2024 |
|
Barclays | 50k | $454k | 162% | Sep 2024 |
|
Bank of New York Mellon | 48k | $434k | 51% | Sep 2024 |
|
Bank of America Corporation | 39k | $351k | 165% | Sep 2024 |
|
Jane Street | 36k | $323k | 33% | Sep 2024 |
|
Jacobs Levy Equity Management | 30k | $274k | 100% | Sep 2024 |
|
Goldman Sachs Group | 27k | $431k | 14% | Jun 2024 |
|
PDT Partners | 27k | $241k | 100% | Sep 2024 |
|
Citigroup | 23k | $209k | 100% | Sep 2024 |
|
Rhumbline Advisers | 21k | $191k | 58% | Sep 2024 |
|
Nuveen Asset Management | 18k | $293k | 36% | Jun 2024 |
|
MetLife Investment Advisors | 14k | $129k | 122% | Sep 2024 |
|
Mirae Asset Global Etfs Holdings | 13k | $116k | 164% | Sep 2024 |
|
Morgan Stanley | 13k | $203k | -9% | Jun 2024 |
|
Alliancebernstein | 11k | $172k | 100% | Jun 2024 |
|
Jpmorgan Chase & Co | 10k | $93k | 136% | Sep 2024 |
|
Values First Advisors | 7.4k | $67k | 100% | Sep 2024 |
|
Wells Fargo & Company | 7.4k | $67k | 123% | Sep 2024 |
|
Bnp Paribas Arbitrage, Snc | 5.5k | $50k | 184% | Sep 2024 |
|
Deutsche Bank Aktiengesellschaft | 4.8k | $44k | 6% | Sep 2024 |
|
New York State Common Retirement Fund | 4.2k | $38k | 0% | Sep 2024 |
|
Royal Bank of Canada | 3.2k | $25k | 226% | Sep 2024 |
|
Summit Investment Advisors | 2.4k | $22k | 133% | Sep 2024 |
|
California State Teachers Retirement System | 1.7k | $16k | 134% | Sep 2024 |
|
Tower Research Capital | 1.6k | $25k | 211% | Jun 2024 |
|
Amalgamated Bank | 623.00 | $6.0k | 0% | Sep 2024 |
|
Nelson, Van Denburg & Campbell Wealth Management | 174.00 | $1.6k | 100% | Sep 2024 |
|
Lazard Asset Management | 33.00 | $0 | 0% | Sep 2024 |
|
Sterling Capital Management | 27.00 | $243.999000 | 100% | Sep 2024 |
|
SRS Capital Advisors | 12.00 | $108.999600 | 0% | Sep 2024 |
|
CWM | 10.00 | $0 | -38% | Sep 2024 |
|
Who sold out of Lexeo Therapeutics?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Artal Group | Jun 2024 | 603k | $9.7M |
Millennium Management | Jun 2024 | 38k | $601k |
Franklin Resources | Jun 2024 | 14k | $225k |
NISA Investment Advisors | Jun 2024 | 32.00 | $512.998400 |
GAMMA Investing | Jun 2024 | 14.00 | $224.999600 |